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Proteomics is a powerful method used to identify, characterize, and quantify proteins within biologic samples. Pancreatic cystic
neoplasms are a common clinical entity and represent a diagnostic and management challenge due to diﬃculties in accurately
diagnosing cystic lesions with malignant potential and assessing the risk of malignant degeneration. Currently, cytology and other
biomarkers in cyst ﬂuid have had limited success in accurately distinguishing both the type of cystic neoplasm and the presence
of malignancy. Emerging data suggests that the use of protein-based biomarkers may have greater utility in helping clinicians
correctly diagnose the type of cyst and to identify which cystic neoplasms are malignant. Several candidate proteins have been
identiﬁed within pancreatic cystic neoplasms as potential biomarkers. Future studies will be needed to validate these ﬁndings and
move these biomarkers into the clinical setting.
1.Background
Pancreatic cysts are increasing in prevalence as cross-
sectional imaging has become widely utilized. In recent
population-based studies using magnetic resonance imaging
(MRI) [1–4] and computerized tomography (CT) scans
[5, 6], the estimated prevalence of cystic lesions ranges
from 2.6% to as high as 44.7%. An autopsy study of
300 patients from Japan reported a prevalence of 24.3%
[7]. Not surprisingly, the number of evaluations for these
lesions is increasing [8, 9]. Management of these increasingly
prevalent lesions can utilize a signiﬁcant amount of health
care resources in the form of diagnostic studies and surgical
resections. Therefore, developing an accurate and cost-
eﬀective diagnostic test to assist in patient management is a
clear priority.
This paper will focus on cystic neoplasms which are
distinguished by the presence of mucinous or nonmucinous
epithelium. Ninety percent of all cystic neoplasms are
comprised of serous cystadenomas (SCAs), a non-mucinous
lesion, as well as mucin-producing cystic tumors comprised
of mucinous cystic neoplasms (MCNs) and intraductal
papillary mucinous neoplasms (IPMNs) [10]. Rare cystic
neoplasms include solid pseudopapillary lesions, lymphoep-
ithelial cysts, and cystic degeneration of pancreatic ductal
adenocarcinoma or neuroendocrine tumors (see Table 1).
The most common nonneoplastic cyst is a pancreatic
pseudocyst which is associated with acute pancreatitis and
has no epithelium.
SCAs are characterized by bland cuboidal glycogen-rich
epithelium. They tend to occur predominantly in women
(87%) with a median age in the early 50s [11, 12]. SCAs are
usually comprised of microcystic components, with a classic
honeycomb appearance, though they can be macrocystic
in appearance [12]. Up to 30% of these lesions will have
a characteristic central scar. Their malignant potential is
considered so low that they are generally not resected unless
symptomatic.
MCNs have columnar mucinous epithelium with sur-
rounding ovarian stroma (deﬁned as hypercellular spindle2 International Journal of Proteomics
Table 1: Types of pancreatic cystic neoplasms.
Mucinous
Mucinous cystic neoplasm
Intraductal papillary mucinous neoplasm (IPMN)
Non-mucinous
Serous cystadenoma
Solid pseudopapillary neoplasm
Lymphoepithelial cysts
Cystic degeneration of ductal adenocarcinoma
Cystic neuroendocrine tumor
Cystic acinar cell carcinoma
cell bundles that lay just beneath the epithelium and
usually show positive staining for estrogen and progesterone
receptors) [13, 14] and typically present as large solitary
macrocystic lesions in the body or tail of the pancreas [15].
They are thought to be separate from the main pancreatic
duct but can be connected in up to 20% of cases [14]. They
occuralmostexclusivelyinwomen(95–98%)[14]duringthe
fourth or ﬁfth decades of life [15]. The rate of malignancy
ranges from 6–30% at the time of resection [15–17]. Risk
factors for malignancy include older age, the presence of a
mural nodule with the cyst, and cyst size >4cm[14, 15, 17].
Theﬁve-yearsurvivalis100%inpatientswithbenigndisease
and 60% in those patients that develop invasive carcinoma
[17, 18]. Recurrence appears to occur only with invasive
disease [15, 19].
IPMNs are characterized by columnar papillary muci-
nous epithelium that involves the main pancreatic duct,
the side branch ducts (SB-IPMN) or both (mixed IPMN).
IPMNs tend to occur more frequently in the head of the
pancreas than the body and tail. Males have a slightly
higher predilection for IPMNs than females do. The risk of
malignancyismuchhigherinmainductdisease(mean70%)
than side-branch disease (mean 25%) [20]. The reported
overall 5-year survival rate for resected noninvasive IPMN
ranges from 77 to 100%, whereas 5-year survival rate for
invasive IPMN ranges from 30% to 75% [21].
Recently, IPMNs have been categorized into four epithe-
lial subtypes—gastric, intestinal, pancreaticobiliary, and
oncocytic, based upon cell morphology and expression
patterns of glycoproteins containing mucin (MUC) [22].
Combinations of epithelium subtypes may be present within
an individual lesion and therefore each IPMN is classiﬁed by
the dominant component [22]. Based upon recent studies,
these categories may explain the clinical behavior of the
diﬀerent IPMN subtypes [23, 24]. Gastric-type IPMNs
primarily are located in the side branches and express
MUC5AC but not MUC1 or MUC2 [23]. These rarely
undergo malignant transformation [23], but if they do,
they develop into tubular adenocarcinomas, which have a
survival that is almost as poor as ductal adenocarcinoma
[24]. Intestinal-type IPMNs are located mainly in the main
pancreatic duct and express both MUC2 and MUC5AC [22].
These have a high frequency of malignant transformation
to colloid carcinoma, which has a better prognosis than
ductal adenocarcinoma [23, 24]. When compared to the
other subtypes of IPMN, pancreaticobiliary-type IPMN is
noted to occur more frequently in women than men and
at a later age (mean 69.2y versus 60.3–65.6y) [23]. By
immunohistochemistry, they express MUC1 and MUC5AC
[22, 23] and may progress to tubular adenocarcinoma [23,
24]. The oncocytic-type IPMNs also express MUC5AC and
MUC1 [22]. These tend to develop in people at a younger
age than the other IPMN subtypes [23]. While these can
progress to malignancy (oncocytic adenocarcinoma), they
tend to be noninvasive [23] and have better survival than
ductal adenocarcinoma [23, 24].
To date, the subtypes of mucinous tumors (MCN and
IPMN) can only reliably be distinguished by surgical pathol-
ogy. There are no presurgical tests that distinguish these cyst
types with a high level of accuracy. Moreover, the triggers
or markers for malignant transformation are unknown and
the timeline to transformation remains unclear. As such,
our knowledge of the natural history of these lesions is still
limited.
In 2006, International Consensus Guidelines were devel-
oped by a team of experts to deﬁne management of cystic
mucinousneoplasms[20].Forcysticneoplasms,thedecision
to undergo surgical resection versus surveillance should be
tempered by patient’s wishes, comorbidities, life expectancy,
and the risk of malignancy versus the risk of surgery. If the
patient is an appropriate surgical candidate, the guidelines
suggest resection of all MCNs and any IPMN which involve
the main duct, or side branch IPMN lesions that are symp-
tomatic, have a solid component, or are >3cminsize[20].
They recommend yearly surveillance for lesions <10mm,
and surveillance every 6–12 months for lesions 10–20mm
and every 3–6 months for lesions >20mm. The surveillance
interval can be lengthened after two years of no change [20].
A retrospective study of 147 patients demonstrated that the
algorithm proposed by the guidelines had a sensitivity and
negative predictive value of 100% but a speciﬁcity of 23%
[25]. Other studies have shown similar results [26–30]. The
algorithm therefore seems reasonably sensitive to identify
those who do not need surgery, but given the low speciﬁcity,
there remains a fairly high resection rate for patients with
benign disease [21].
The clinical challenges of managing patients with pan-
c r e a t i cc y s t i cn e o p l a s m sh a v es e v e r a ll a y e r so fc o m p l e x i t y .
First, one must diﬀerentiate between mucinous and non-
mucinous cysts. This diﬀerentiation is important because
their clinical management is diﬀerent. Non-mucinous
lesions generally do not require follow-up, whereas because
of their premalignant potential, mucinous neoplasms are
either resected or monitored in a surveillance program.
Second, once a mucinous lesion is identiﬁed, one should
distinguishbetweenMCNandIPMN(inparticularfocalSB-
IPMN)sincetheformershouldberesectedwhereasthelatter
can be monitored. This can be a diﬃcult task in part because
MCNs occasionally have communication with the main duct
which is sometimes diﬃcult to accurately identify by cross-
sectional imaging or EUS [10, 20]. Moreover, there is no
preoperative test that can identify the characteristic ovarianInternational Journal of Proteomics 3
stroma of MCNs [10], and even on surgical pathologic
analysis, the stroma may not be uniformly present, partic-
ularly with malignant transformation [31]. Third, amongst
the mucinous lesions, one must diﬀerentiate between those
that have high-grade dysplasia and cancer and those that
are benign in order to appropriately refer those patients
to surgery who would most beneﬁt from resection. This
diﬀerentiation would allow more selective recommendation
of surgical resection for those who truly need it. Finally,
given that the natural history of these lesions remains to be
clariﬁed, one must be able to identify those lesions that will
go onto malignant transformation. To date, no single test
or tests adequately addresses these challenges and as such, a
biomarkerorsetofbiomarkersareneededinordertoaddress
all four of these challenges.
Current tests have limited ability to distinguish between
mucinous and non-mucinous lesions or to identify malig-
nant cysts (Figure 1). Cross-sectional radiologic imaging is
limited in its ability to distinguish between the diﬀerent
types of cysts. The accuracy of CT and MRI to determine
the correct histology ranges from 40–60% [32, 33]. New
advances in CT and MRI technology that provide more
detailed images may account for a modest increase in accu-
racy up to 84% [34]. Morphology by endoscopic ultrasound
is also limited in its ability to distinguish between types of
cystic tumors, with a sensitivity and speciﬁcity of 56% and
45%, respectively [35]. Furthermore, the accuracy of EUS
morphology is limited by a lack of interobserver agreement
[36].
Endoscopic ultrasound allows for ﬁne needle aspiration
of cyst ﬂuid analysis. The tests of choice for diagnostic
evaluation include cytology and carcinoembryonic antigen
(CEA).Fluidcytologycanbelimitedduetoluminalcontam-
ination, highly variable amounts of extracellular mucin, and
scant cellularity within the cyst [37]. The overall accuracy
of cytology in identifying mucinous lesions is around 50%
[35, 38]. There are no cytological ﬁndings which currently
distinguish MCN from IPMN [39, 40]. Cytology has a
speciﬁcity that approaches 100% but lower sensitivity in
identifying the presence of malignancy [38, 41, 42]. To date,
cyst ﬂuid CEA remains the most accurate test to distinguish
mucinous from non-mucinous cysts [35]. A prospective,
multicenter study determined that a CEA >192ng/mL had
a 75% sensitivity and 85% speciﬁcity in distinguishing
between mucinous and non-mucinous cysts. Its overall
accuracy of 79% was higher than morphology, cytology, and
othertumormarkerspreviouslyidentiﬁedinpancreaticcysts
such as CA72-4 [43], CA19-9 [44], and CA 15-3 [35, 45].
However, ﬂuid CEA is limited by the fact that there is broad
overlap between types of lesions. In addition, this test is
unable to distinguish between types of mucinous cysts, nor
is there any correlation between elevated concentrations and
risk of malignancy [46].
2. Biomarkers for Cystic Neoplasms
As a result of these current limitations, there has been
considerable interest in ﬁnding other biomarkers that can
better distinguish mucinous lesions and identify patients
with tumors of higher malignant potential (i.e., with high-
grade dysplasia or carcinoma) who would beneﬁt most from
surgical resection. The general approach that has been taken
is to aspirate cyst ﬂuid and use a variety of techniques to
try to create highly sensitive and speciﬁc assays to identify
subjects with high grade dysplasia or frank malignancy [47].
Pancreatic cyst ﬂuid would appear to be an ideal source for a
biomarkerdevelopmentduetoitsrelativeeaseatobtainment
by endoscopic ultrasound, which has a low complication
rate when performed by an experienced endoscopist, and the
presumed localization of relevant biological material from
cyst epithelium [48].
There is a considerable interest in genetic material within
cyst ﬂuid and its potential as to serve as biomarkers. DNA
mutations, such as K-ras, and allelic loss amplitude of a
proprietary list of speciﬁc pancreatic cancer-related genes
w i t h i nc y s tﬂ u i dh a v eb e e ns t u d i e da ss u r r o g a t em a r k e r sf o r
mucinous and malignant cysts [49]. In a multicenter study
of 113 patients, the authors reported that the presence of
a cyst ﬂuid K-ras mutation had a high speciﬁcity of 95%
but low sensitivity of 45% for diagnosing mucinous cysts.
The combination of a K-ras mutation followed by allelic loss
showed a high speciﬁcity of 96% but a low sensitivity of 37%
in diagnosing malignant cysts [49]. Subsequent studies have
reported mixed correlation between these DNA mutations
and ﬁnal surgical pathology [50–52]. The added beneﬁt over
existing tests remains unclear, and as such, the role for DNA
analysis will need to be clariﬁed [46, 53].
MicroRNAs (miRNAs) are small (22 nucleotides) non-
coding RNAs that regulate the stability and translation
of mRNA transcripts. Deregulation of miRNA expression
has been identiﬁed in several human cancers, including
pancreatic adenocarcinoma [54–59]. Using a panel of 12
miRNAs that are upregulated in pancreatic cancer, Habbe
et al. described the identiﬁcation of abnormal miRNA
expression in surgical histology from 15 noninvasive IPMNs
compared to normal pancreatic tissue [60]. Moreover, they
established the feasibility of identifying miRNA in pancreatic
juice. The two miRNAs with the highest expression, miR-21
and miR-155, both of which have been shown in laboratory
studies to inhibit apoptosis, had higher expression in the
IPMNs (6 of 10, 60%) than normal controls (0 of 5), though
this did not reach statistical signiﬁcance due to a small
number of samples. There was also an increased frequency of
miR-155 expression in IPMN lesions with pancreaticobiliary
and intestinal epithelium. Further studies will be required to
validate these ﬁndings and to deﬁne the true utility of using
miRNAs as biomarkers in pancreatic cyst ﬂuid.
3. Protein-BasedBiomarker Strategies
Another strategy for biomarker development is to identify
speciﬁc proteins already known to be involved in pancreatic
cancer. One group used multiplex assays with 54 proteins
associated with pancreatic cancer to demonstrate diﬀerential
protein expression between noninvasive IPMN and SCA (34
out of 51 proteins, 67%) and noninvasive MCN and SCA4 International Journal of Proteomics
(a) (b)
(c) (d)
Figure 1: These images highlight the limitations of cross-sectional imaging and endoscopic ultrasound (EUS) in diﬀerentiating cyst types.
By CT ((a)+(c)) and by EUS ((b)+(d)), the two cysts look very similar. The cyst in (a) and (b) was a macrocystic serous cystadenoma and
the cyst in (c) and (d) was a mucinous cystadenoma. The histology of both was conﬁrmed by surgical resection.
(13 out of 51 proteins, 25%) [61]. When using a panel of 14
proteins, the accuracy of distinguishing IPMNs from SCAs
was 92% [61]. Another group took a more speciﬁc approach
and examined the role of Prostaglandin E(2), which they
had shown to have increased expression in pancreatic cancer
tissue over normal pancreatic tissue [62], in distinguishing
between types of mucinous cysts. From ﬂuid obtained from
58 resected cystic lesions, they demonstrated that cyst ﬂuid
PGE(2) concentrations were greater in IPMNs versus MCNs
(2.2 ± 0.6v e r s u s0 .2 ± 0.1pg/mol,P<0.05) and that the
mean level of PGE(2) increased with the degree of dysplasia
in IPMN lesions [63]. However, there was noted to be an
overlap in PGE(2) concentrations in benign MCNs (n =
11) and SCAs (9n = 5), thereby limiting the utility of this
biomarker in the clinical setting. These studies demonstrate
that targeting proteins associated with pancreatic cancer
show potential in identifying appropriate biomarkers for
cystic lesions and will require further investigation and
validation.
As described above, immunohistochemistry of surgical
pathology has demonstrated diﬀerential mucin proﬁles in
IPMN [64, 65] and it would seem logical to expect mucin
proﬁles in cyst ﬂuid to identify lesions at risk for malig-
nancy. A recent study has demonstrated diﬀerential mucin
expression in cyst ﬂuid from 40 surgically resected IPMNs
using enzyme-linked immunosorbent assays [66]. Patients
with high grade dysplasia or carcinoma (n = 19) were
categorized as “high risk.” Cyst ﬂuids MUC2 and MUC4
were elevated in high-risk patients as compared to low
risk patients (10 ± 3.0ng/mL versus 4.4 ± 1.2ng/mL,P =
0.03; 20.06 ± 10.6ng/mL versus 4.5±1.4ng/mL, P = 0.03,
resp.). There was no diﬀerence in MUC1 or MUC5AC
concentrations between the two groups. Cysts with gastric
epithelium (n = 23) had statistically signiﬁcant lower
expressions of MUC2, MUC4, and MUC5AC compared to
pancreatic cystic tumors without gastric epithelium. Cysts
with intestinal epithelium (n = 8) had statistically signiﬁcant
higher elevations of MUC2 compared to nonintestinal
cysts and a trend towards higher MUC4 concentrations.
There was no discernible diﬀerence in MUC concentrations
in pancreaticobiliary epithelium cysts compared to those
without pancreaticobiliary epithelium. These ﬁndings haveInternational Journal of Proteomics 5
not yet been validated; however, this study highlights the
potential for risk stratiﬁcation based upon MUC expression
in cyst ﬂuid.
Other proteins previously identiﬁed in pancreatic cancer
have also been studied to more accurately identify IPMN
harboring malignancy. Mutant K-ras protein has been
identiﬁed in cyst ﬂuid using mass spectrometry [67]. The
expression of Plectin-1, a marker found to be increased in
ductaladenocarcinoma,hasalsobeenidentiﬁedinﬂuidfrom
malignant mucinous cysts [68]. Cytokine IL-1β is markedly
elevated in high-risk patients compared to low risk patients
in a small number of IPMNs [69]. These ﬁndings have yet to
be validated and are thus far experimental in nature.
4. Proteomics of CystFluid
Proteomics is an attractive method for identifying proteins
within the cyst ﬂuid which can diﬀerentiate mucinous cysts
or identify malignancy with greater accuracy. Traditionally,
proteins are separated by two-dimensional gel electrophore-
sis with subsequent mass spectrometric identiﬁcation of
protein spots or by protein digestion and mass spectrometric
identiﬁcation of peptide sequences. Proteomics overcomes
the shortcoming of using DNA or mRNA analysis, whose
c h a n g e sm a yn o tr e ﬂ e c ta c t u a lp r o t e i ne x p r e s s i o n[ 70, 71]
or include posttranslational modiﬁcations. Furthermore,
proteomic analysis may provide information on the patho-
genesis of these lesions.
The challenge of using proteomics is the complexity of
the proteome. The method can identify a large number of
proteins but interpretation of the results may be clouded
by the signal of the most abundant proteins, and thus
proteins present in very small concentrations may not be
easy to identify. Within the pancreatic cyst ﬂuid itself, the
vast variety of proteins are a reﬂection of cyst epithelium,
luminal contamination (if ﬂuid is obtained by transgastric or
transduodenalaspiration),plasmaproteins,mucus,andpos-
sibly pancreatic enzymes, if there is a connection of the cyst
to the pancreatic ductal system. Protein concentration yield
may be subject to degradation by endogenous peptidases
[72] or post-translational modiﬁcations [73]. Proteomics
has been used to successfully identify potential biomarkers
in the tissue [74, 75], serum [76], and pancreatic juice
[77, 78] of patients with pancreatic ductal adenocarcinoma.
A method to perform proteomic analysis using paraﬃn-
embedded archival slides of a noninvasive IPMN carcinoma-
in-situ has also been described [79].
Interest in using proteomics in pancreatic cyst ﬂuid
analysis is growing. The feasibility of proteomic analysis
of pancreatic cyst ﬂuid was established by Scarlett et al.
[80]. In this proof of concept study, cyst ﬂuids from 10
patients (including 3 ductal adenocarcinomas, 2 mucinous
cystadenoma, and 1 IPMN) were analyzed using SELDI-
TOF mass spectrometry. Reproducible protein proﬁles were
demonstrated amongst the adenocarcinoma patients with
diﬀerential expression in twelve protein peaks identiﬁed.
These ﬁndings suggest that proteomics is a viable method for
identifying potential biomarkers within cyst ﬂuid.
Two recent studies advanced the use of proteomic
analysis to identify biomarkers in cyst ﬂuid. Ke et al. used
small volumes (<40μL) from EUS ﬁne needle aspirates and
grouped patients according to their cytology results ((a)
benign:noevidenceofbenignmucinousepithelium,atypical
cells or carcinoma; (b) benign mucinous epithelium; (c)
atypical/suspicious; (d) malignant) [81]. Fluid was analyzed
using MALDI-TOF mass spectrometry with LC/MS/MS pro-
tein identiﬁcation, 2D gel electrophoresis, or GeLC/MS/MS
(tryptic digestion of proteins fractionated by SDS-PAGE and
identiﬁed by LC/MS/MS). The ﬁrst two techniques proved to
be unsatisfactory, presumably from endogenous peptidases
which splintered native proteins in numerous locations [81].
Mass spectrometry yielded homologs within three families
of proteins associated with pancreatic cancer, including
mucins, CEACAMs, and S100s. The authors conclude that
LC/MS/MS mass spectrometry provides useful information
on biomarkers within cyst ﬂuid using small volumes of ﬂuid.
T h es a m et e c h n i q u ew a su s e db yC u o g h ie ta l .i nas t u d y
of 8 patients who underwent surgical resection for symp-
tomatic pancreatic neoplasms. Fluid was aspirated directly
from the surgical specimens, thereby avoiding potential gas-
trointestinal luminal contamination. Proteins wereseparated
by SDS-PAGE and then analyzed by LC/MS/MS. The total
number of proteins identiﬁed in the cyst samples ranged
from 220 to 727. They identiﬁed 38 proteins unique to
neuroendocrine tumors, 18 unique to serous cystadenomas,
92 unique to MCNs, and 29 unique to IPMNs. Analysis of
known proteins revealed that several proteins identiﬁed in
the mucinous lesions (MCNs and IPMNs) were previously
reported to be upregulated pancreatic cancer-associated
proteins. The ﬁndings were conﬁrmed by immunohisto-
chemistry for two of the identiﬁed proteins, olfactomedin-4
(OLFM4) and the cell surface glycoprotein MUC18. Clearly,
proteomics shows great promise in identifying potential
biomarkers (see Table 2). Further studies and reﬁnement of
technique will hopefully yield reliable candidate biomarkers
that can be validated in clinical studies.
5. Glycoproteomics
Glycoproteomics speciﬁcally examines carbohydrate modiﬁ-
cation or glycosylation of proteins. Aberrant glycosylation is
a hallmark for tumorigenesis and tumor progression and not
surprisingly, many previously identiﬁed biomarkers are gly-
coproteins. The advantage of glycoproteomics is the focused
isolation of glycoproteins by speciﬁc binding of glycosylation
sites. This speciﬁcity reduces the complexity of sample
protein populations. As such, this method signiﬁcantly
increasesthedetectionsensitivityforlowabundanceproteins
[84]. Analytic approaches have been broadly categorized as
glycoprotein-based analysis or glycopeptide-based analysis
[84,85].Theformerbeginswithenrichmentofglycoproteins
using lectin and separation techniques to enrich the protein
fractions. The latter uses glycopeptides that are digested and
then deglycosylated. Peptide identiﬁcation is then performed
by mass spectrometry.6 International Journal of Proteomics
Table 2: Potential biomarkers identiﬁed to date in pancreatic cyst
ﬂuid.
Genetic biomarkers References
DNA-based
K-ras [49]
Allelic loss amplitude [49]
RNA-based
miR-21 [60]
miR-155 [60]
Protein-based biomarkers
Prostaglandin E(2) [63]
Interleukin-1β [69]
MUC1 [81, 82]
MUC2 [66]
MUC4 [66]
MUC5AC [81–83]
MUC5B [81]
MUC6 [81, 83]
MUC16 [81]
MUC18 [83]
CA 19-9 [82]
Plectin-1 [68]
S100-A6, 8, 9, 11 [81]
CEACAM 1, 5, 6, 7 [81]
BGP-1 [83]
Tspan-8, 27, 28 [83]
CD55 [83]
E-cad [83]
Glutathione S-transferase P [83]
Olfactomedin-4 [83]
Prostate stem cell antigen [83]
Pyruvate kinase isozymes M1/M2 [83]
Ras-related protein Rab-8A [83]
Rho-related GTP-binding protein RhoC [83]
Trefoil factor 1,2 [83]
VE-cadherin [83]
Protein-Z-dependent protease inhibitor [83]
von Willebrand antigen 2 [83]
Glycoproteomics has already shown promise as a
biomarker development tool in pancreatic cancer. A tech-
nique using lectin aﬃnity chromatography, liquid sepa-
ration, and characterization by mass spectrometry was
demonstrated in serum of patients with pancreatic cancer
[85]. Sialylated plasma protease C1 inhibitor was shown
to be downregulated in cancer serum. Downregulation of
the N83 glycosylation sites was also observed. Ninety-two
individual glycosylation sites with 41 glycoproteins were
identiﬁed and 202 glycan peaks with 104 unique carbohy-
drate structures were detected during glycan proﬁling using
diﬀerent separation techniques. Forty-ﬁve oligosaccharides
were found altered in pancreatic cancer serum of which
44 were distinct in the cancer sample [85]. Based on
these promising results, glycoprotein microarrays have been
created as a high throughput tool to diﬀerentiate serum
samples from patients with pancreatic cancer, from chronic
pancreatitis and normal subjects [86, 87].
This approach has been expanded to the use of glyco-
proteomics in cystic neoplasms. Using a novel antibody-
lectin sandwich array (ALSA) that targets glycan moieties on
proteins [88], Haab et al. measured protein expression and
glycosylation of MUC1, MUC5AC, MUC16, CEA, and other
proteins associated with pancreatic cancer in 53 cyst ﬂuid
samples from surgically resected lesions (17 MCN, 15 IPMN,
15 SCA, and 9 pseudocysts) [82]. Wheat germ agglutination
of MUC5AC was markedly elevated in MCN and IPMN but
not SCAs or pseudocysts. CA19-9 could distinguish between
MCN and IPMN with a sensitivity and speciﬁcity of 82%
and 93%, respectively. MUC1 was elevated in serous lesions
compared to pseudocysts and mucinous cysts. MUC5AC in
combination with CA19-9 (sensitivity 87%, speciﬁcity 86%)
outperformed ﬂuid CEA (37% sensitivity, 80% speciﬁcity)
in distinguishing mucinous from nonmucinous cysts. This
study shows that glycan variants of proteins within cyst
ﬂuid may prove to be useful biomarkers and highlights
an area warranting further evaluation. Validation studies
are currently in progress. In addition, it remains to be
determined if this approach will be useful in separating
malignant and non-malignant lesions.
6. Conclusions
The clinical management of pancreatic cystic neoplasms is
diﬃcult due to the lack of suﬃciently sensitive and speciﬁc
diagnostic tests to diﬀerentiate cyst types and the presence
of malignancy. Pancreatic cyst ﬂuid provides an appealing
source for improved biomarker development, particularly
by proteomic analysis. Preliminary work with cyst ﬂuid
glycosylated mucins show promise in distinguishing muci-
nous from non-mucinous cysts and diﬀerentiating types of
mucinous cysts. Cyst ﬂuid homologs of mucin, CEACAMs
and S100s, and other proteins associated with pancreatic
tumorigenesis have been identiﬁed as potential biomarkers
for malignancy within cyst ﬂuid. These results will all
need to be studied and validated in larger more adequately
sized test and training sets of pancreatic cyst ﬂuid for full
biomarker development. Given that the ﬁeld is currently
limited by the lack of adequate numbers of pancreatic cyst
ﬂuid samples for analysis, it will be important that resources
for ﬂuid samples are further developed. As we close our
gaps in knowledge regarding natural history of mucinous
cysts and the relationship between epithelial subtypes and
prognosis, biomarkers will likely play a prominent role in the
management of cystic neoplasms.
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